• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Stryker sees pandemic sales effects softening

Stryker sees pandemic sales effects softening

April 28, 2021 By Nancy Crotti

StrykerStryker (NYSE:SYK) executives see hip and knee procedures growing in 2021, based on a trend that started in March and continued in April.

Such elective procedures were still sluggish in early 2021 due to the pandemic. Still, regional recovery from COVID-19 — particularly in the U.S. and Asia — bodes well for the company, CEO Kevin Lobo told analysts on the company’s first-quarter 2021 earnings call.

Stryker posted strong international sales of medical/surgical and sports medicine equipment compared with 2019, which Stryker execs chose for comparison purposes rather than 2020. The company also had double-digit organic growth (12.8%) in its interventional spine and neurotech businesses.

Sales of Stryker’s Mako robotic systems had a “banner” first quarter, Lobo said on the call, transcribed by Seeking Alpha, following similar positive results in Q4 2020. Mako sales lifted “other ortho” U.S. sales by 49% in the U.S. Stryker has not shared its Mako sales number for several quarters. Still, Lobo said he is hopeful, given the 4,500 hospitals that could use a Mako robotic system, and some even more than one.

“It was really Mako around the world that was booming in the first quarter, and that gives us a lot of optimism because that’s an early indicator of future implants growth,” Lobo said.

Stryker’s orders for large- and small-capital equipment are both picking up, the CEO added, contributing to its confidence in its full-year outlook. Neurovascular sales also did well in Q1, following a strong fourth quarter.

Stryker expects adjusted net earnings per diluted share to be in the range of $9.05 to $9.30 in 2021, up from the previous guidance of $8.80 to $9.20. The company still expects 2021 organic net sales growth to be in the range of 8% to 10% from 2019.

The integration of Wright Medical, acquired for $4.7 billion in November 2020, continues apace, added Stryker CFO Glenn Boehnlein.

The Kalamazoo, Mich.–based orthopedic device giant late yesterday reported profits of $302 million, or $0.79 per share, on sales of $3.953 billion for the three months ended March 31, 2021, for a bottom-line decline of –38.7 % on sales growth of 10.2% compared with Q1 2020.

Adjusted to exclude one-time items, earnings per share were $1.93, 6¢ behind The Street, where analysts were looking for EPS of $1.99 on sales of $3.96 billion.

Stryker faces several headwinds through the remainder of the year that may result in a “relatively noisy 2021” according to analysts at Truist Securities.

“Beyond potential integration issues with Wright, we think competition in robotics may intensify, and MedSurg comps ahead will become more difficult,” they wrote. “While we think the company has proven an ability to execute historically, we continue to see more attractive investment opportunities in large-cap medtech at this time.”

SVB Leerink analyst Richard Newitter was more positive about Stryker.

“Over the next two years, we view SYK as one of the best-positioned companies in our large-cap universe to sustain ‘upper-tier’ organic sales/EBITDA/EPS growth and to drive shareholder returns,” Newitter wrote in a note to investors. He cited these reasons for the outlook:

  • New product cycles across divisions should help support divisional sales growth at or above rates for key end-markets.
  • Growing exposure/market share within several faster-growing medtech subsectors (i.e., extremities, neurovascular, reprocessing, robotics).
  • Increasing growth contributions from the Sage, Physio-Control, Invuity, K2M acquisitions, and eventually Wright Medical.
  • Longer-term potential to generate significant incremental revenues from the MAKO platform in spine & extremities.

“As investors increasingly focus on these sales growth factors and operating leverage opportunities into the future, we believe the stock can move higher,” Newitter said.

Filed Under: Business/Financial News, Featured, Orthopedics Tagged With: Stryker, SVB Leerink, Truist Securities

More recent news

  • Autonomix picks up key nerve ablation catheter patent
  • Affluent Medical can move to pivotal phase of artificial urinary sphincter study
  • Globus Medical announces $500M share repurchase program
  • Cook Medical warns of issue with angiographic catheter
  • Virtuoso Surgical reports first cases with robotic endoscopy system, plans FDA IDE submission

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy